Shell Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $2.61M | Sell |
6,666
-10,515
| -61% | -$4.39M | 0.26% | 73 |
|
|
2025
Q2 | $7.65M | Buy |
17,181
+3,809
| +28% | +$1.76M | 0.26% | 68 |
|
|
2025
Q1 | $6.48M | Sell |
13,372
-1,285
| -9% | -$599K | 0.31% | 54 |
|
|
2024
Q4 | $5.9M | Buy |
14,657
+79
| +0.5% | +$36.6K | 0.26% | 66 |
|
|
2024
Q3 | $6.78M | Buy |
+14,578
| New | +$7M | 0.3% | 63 |
|
|
2024
Q1 | $7.53M | Sell |
16,074
-77
| -0.5% | -$32.6K | 0.34% | 53 |
|
|
2023
Q4 | $6.57M | Sell |
16,151
-2,817
| -15% | -$1.04M | 0.3% | 64 |
|
|
2023
Q3 | $6.6M | Sell |
18,968
-212
| -1% | -$74.1K | 0.27% | 67 |
|
|
2023
Q2 | $6.75M | Buy |
19,180
+919
| +5% | +$310K | 0.27% | 68 |
|
|
2023
Q1 | $5.75M | Sell |
18,261
-41
| -0.2% | -$12.3K | 0.24% | 87 |
|
|
2022
Q4 | $5.29M | Sell |
18,302
-5,523
| -23% | -$1.68M | 0.23% | 90 |
|
|
2022
Q3 | $6.9M | Sell |
23,825
-5,375
| -18% | -$1.55M | 0.27% | 71 |
|
|
2022
Q2 | $8.23M | Sell |
29,200
-3,821
| -12% | -$1.02M | 0.24% | 79 |
|
|
2022
Q1 | $8.62M | Buy |
33,021
+4,182
| +15% | +$993K | 0.2% | 103 |
|
|
2021
Q4 | $6.33M | Sell |
28,839
-8,012
| -22% | -$1.56M | 0.13% | 166 |
|
|
2021
Q3 | $6.68M | Sell |
36,851
-17,808
| -33% | -$3.48M | 0.15% | 149 |
|
|
2021
Q2 | $11M | Sell |
54,659
-7,709
| -12% | -$1.61M | 0.21% | 112 |
|
|
2021
Q1 | $13.4M | Sell |
62,368
-14,921
| -19% | -$3.28M | 0.27% | 84 |
|
|
2020
Q4 | $18.3M | Buy |
77,289
+25,367
| +49% | +$5.82M | 0.38% | 49 |
|
|
2020
Q3 | $14.1M | Sell |
51,922
-322
| -0.6% | -$88.8K | 0.33% | 63 |
|
|
2020
Q2 | $15.2M | Buy |
52,244
+36,049
| +223% | +$9.77M | 0.38% | 55 |
|
|
2020
Q1 | $3.85M | Sell |
16,195
-1,811
| -10% | -$415K | 0.11% | 212 |
|
|
2019
Q4 | $3.94M | Sell |
18,006
-507
| -3% | -$103K | 0.08% | 269 |
|
|
2019
Q3 | $3.14M | Sell |
18,513
-2,438
| -12% | -$431K | 0.07% | 282 |
|
|
2019
Q2 | $3.84M | Buy |
20,951
+964
| +5% | +$169K | 0.09% | 256 |
|
|
2019
Q1 | $3.68M | Buy |
19,987
+1,314
| +7% | +$243K | 0.08% | 268 |
|
|
2018
Q4 | $3.09M | Sell |
18,673
-5,060
| -21% | -$877K | 0.08% | 266 |
|
|
2018
Q3 | $4.57M | Sell |
23,733
-1,067
| -4% | -$190K | 0.09% | 249 |
|
|
2018
Q2 | $4.21M | Buy |
24,800
+1,323
| +6% | +$205K | 0.09% | 259 |
|
|
2018
Q1 | $3.83M | Sell |
23,477
-1,207
| -5% | -$197K | 0.08% | 274 |
|
|
2017
Q4 | $3.7M | Buy |
24,684
+3,142
| +15% | +$465K | 0.07% | 276 |
|
|
2017
Q3 | $3.27M | Sell |
21,542
-6,363
| -23% | -$958K | 0.07% | 279 |
|
|
2017
Q2 | $3.6M | Sell |
27,905
-1,614
| -5% | -$194K | 0.08% | 267 |
|
|
2017
Q1 | $3.23M | Buy |
29,519
+1,141
| +4% | +$100K | 0.07% | 281 |
|
|
2016
Q4 | $2.09M | Sell |
28,378
-1,297
| -4% | -$106K | 0.05% | 379 |
|
|
2016
Q3 | $2.59M | Sell |
29,675
-1,384
| -4% | -$131K | 0.05% | 345 |
|
|
2016
Q2 | $2.67M | Buy |
31,059
+6,799
| +28% | +$587K | 0.06% | 314 |
|
|
2016
Q1 | $1.93M | Sell |
24,260
-174
| -0.7% | -$15.7K | 0.05% | 382 |
|
|
2015
Q4 | $3.08M | Sell |
24,434
-22,019
| -47% | -$2.66M | 0.07% | 266 |
|
|
2015
Q3 | $5.22M | Buy |
46,453
+13,777
| +42% | +$1.77M | 0.08% | 218 |
|
|
2015
Q2 | $4.04M | Sell |
32,676
-7,017
| -18% | -$884K | 0.08% | 253 |
|
|
2015
Q1 | $4.68M | Sell |
39,693
-10,225
| -20% | -$1.23M | 0.08% | 242 |
|
|
2014
Q4 | $5.93M | Buy |
49,918
+3,465
| +7% | +$390K | 0.1% | 223 |
|
|
2014
Q3 | $5.22M | Buy |
46,453
+6,829
| +17% | +$650K | 0.08% | 225 |
|
|
2014
Q2 | $3.75M | Sell |
39,624
-228
| -0.6% | -$16K | 0.06% | 293 |
|
|
2014
Q1 | $2.82M | Sell |
39,852
-3,419
| -8% | -$271K | 0.05% | 368 |
|
|
2013
Q4 | $3.21M | Sell |
43,271
-22,574
| -34% | -$1.57M | 0.05% | 324 |
|
|
2013
Q3 | $4.99M | Sell |
65,845
-332
| -0.5% | -$26.4K | 0.09% | 240 |
|
|
2013
Q2 | $5.3M | Buy |
+66,177
| New | +$4.87M | 0.1% | 222 |
|
Other funds holding VRTX
Shell Asset Management's VRTX Position: Q3 2025 in Review
Shell Asset Management reduced its Vertex Pharmaceuticals (VRTX) stake by 61% in Q3 2025, selling an estimated $4.39M and leaving 6,666 shares worth $2.61M. The position accounts for 0.26% of the portfolio, ranked #73.
Shell Asset Management first reported a position in VRTX in Q2 2013 and has held it in 49 quarters since. The position peaked at $18.3M in Q4 2020. 1,520 funds tracked by Wall St. Rank hold VRTX as of Q3 2025.
- Shell Asset Management held 6,666 shares of Vertex Pharmaceuticals worth $2.61M as of Q3 2025.
- Shell Asset Management sold 10,515 Vertex Pharmaceuticals shares in Q3 2025, an estimated $4.39M.
- Vertex Pharmaceuticals made up 0.26% of Shell Asset Management's portfolio in Q3 2025, its #73 holding.
- Shell Asset Management first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 49 quarters since.
- Shell Asset Management's Vertex Pharmaceuticals position peaked at $18.3M in Q4 2020.
- 1,520 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2025.
Based on Shell Asset Management's 13F filing for Q3 2025, filed 7 Nov 2025.